Colorectal Cancer–Derived Foxp3+IL‐17+ T Cells Suppress Tumour‐Specific CD8+ T Cells
Authors:
- 9 June 2011
- journal article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 74 (1) , 47-51
Abstract
The pathogenesis of cancer is remained to be further understood. This study aims to investigate the role of tumour‐derived Foxhead box P3 (Foxp3)+interleukin (IL)‐17+ T cells on suppressing tumour‐specific CD8+ T cells. Colorectal cancer (CRC) tissue was collected from surgically removed cancer tissue of 22 patients with CRC. Foxp3+IL‐17+ T cells in cancer tissue were examined by flow cytometry. A set of cell markers and cytokines expressed by Foxp3+IL‐17+ T cells were determined by immune staining. By coculture with isolated peripheral CD8+ T cells, the immune regulatory capacity of Foxp3+IL‐17+ T cells was examined. The results showed that a number of Foxp3+IL‐17+ T cells were found in CRC tissue (22.8 ± 2.6 cells/mm2 tissue) that was significantly more than in non‐cancer colonic mucosa (5.6 ± 1.04 cells/mm2 tissue). The Foxp3+IL‐17+ cells also CD4+, CCR6+, transforming growth factor (TGF)‐beta+ and IL‐6+. The CD8+ T cells proliferated markedly after exposure to tumour protein in culture that was suppressed in the presence of CRC–derived Foxp3+IL‐17+ T cells; the suppression was attenuated by pretreatment with anti‐IL‐17 antibody. We conclude that CRC–derived Foxp3+IL‐17+ T cells have the ability to suppress tumour‐specific CD8+ T cells. This subset of T cells may be a novel therapeutic target in the treatment of CRC.Keywords
This publication has 18 references indexed in Scilit:
- Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestineGut, 2009
- Identification of IL-17-producing FOXP3+regulatory T cells in humansProceedings of the National Academy of Sciences, 2009
- Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancerArchivum Immunologiae et Therapiae Experimentalis, 2008
- Memory T cells in cancer immunotherapy: which CD8+ T‐cell population provides the best protection against tumours?Tissue Antigens, 2008
- Disruption of T-cell immunoglobulin and mucin domain molecule (TIM)–1/TIM4 interaction as a therapeutic strategy in a dendritic cell–induced peanut allergy modelJournal of Allergy and Clinical Immunology, 2008
- CD8+ T cell efficacy in vaccination and diseaseNature Medicine, 2008
- Therapeutics targeting tumor immune escape: Towards the development of new generation anticancer vaccinesMedicinal Research Reviews, 2007
- Staphylococcal enterotoxin B increases TIM4 expression in human dendritic cells that drives naïve CD4 T cells to differentiate into Th2 cellsMolecular Immunology, 2007
- Tumor antigen-specific T helper cells in cancer immunity and immunotherapyCancer Immunology, Immunotherapy, 2005
- Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxicBritish Journal of Surgery, 2004